ARTICLE | Clinical News

Nektar gains on updated response data for NKTR-214

March 2, 2018 11:35 PM UTC

Nektar Therapeutics (NASDAQ:NKTR) added $18.32 (22%) to $102.87 on Friday after President and CEO Howard Robin said that two additional renal cell carcinoma (RCC) patients who previously achieved stable disease have converted to responders in the Phase Ib portion of the Phase Ib/II PIVOT-02 trial evaluating NKTR-214 plus anti-PD-1 mAb Opdivo nivolumab to treat solid tumors.

Robin reported the updated data in the company's 4Q17 earnings call after market close on Thursday. Friday's move translates to an increase of about $2.9 billion in market cap...